IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Core Insights - IO Biotech is advancing its lead investigational candidate, IO102-IO103, in a pivotal Phase 3 trial for advanced melanoma, with new non-clinical data supporting its efficacy in tumor growth control through T-cell activation [1][2] - The company is also presenting new preclinical data for IO170, which targets TGF-beta, further emphasizing the potential of immune-modulatory therapeutic cancer vaccines [1][2] - The American Association for Cancer Research (AACR) Annual Meeting 2025 will feature presentations on these candidates, highlighting their mechanisms of action and contributions to cancer immunotherapy [1][3] Company Overview - IO Biotech is a clinical-stage biopharmaceutical company focused on developing immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its proprietary T-win platform [6] - The T-win platform aims to activate T cells to target both tumor cells and immune-suppressive cells within the tumor microenvironment [6] - The company has received Breakthrough Therapy Designation from the US FDA for IO102-IO103 in combination with Merck's KEYTRUDA for treating advanced melanoma [6] Presentation Details - Two abstracts will be presented at the AACR Annual Meeting: one on IO102-IO103 and another on IO170, both scheduled for April 28, 2025 [3] - The educational session on cancer vaccines will be chaired by Dr. Mads Hald Andersen, focusing on advancements in cancer vaccine research [3][5]